Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

NCT: NCT05557123 · COMPLETED

NCT IDNCT05557123
StatusCOMPLETED
Start Date2022-03-10
Completion2025-12-16

Brief Summary

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Frequently Asked Questions

What is Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)?

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF) is a clinical trial registered under NCT05557123. Current status: COMPLETED.

What is the status of NCT05557123?

The current status of NCT05557123 (Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)) is: COMPLETED.

When did Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF) start?

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF) started on 2022-03-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑